European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
fumarate 300 mg), formally approving atripla
for commercialization in the
27 countries of the E...mportant step forward in dosing simplification."
has been approved in the European Union for the tr...apy.
The marketing authorization application for atripla
in the European
Union was filed by a three-way joi...
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
... approval by the European
Commission. If approved, atripla
would represent the first and only
once-daily sing...nd Gilead share
responsibility for commercializing atripla
throughout the European Union
and certain other Eu...lead will record revenues from
future net sales of atripla
in most of the European countries, while
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
... - Once Granted by the European Commission, atripla
Would Represent the
First and Only Once-Daily Sin...te 300
mg). Specifically, the CHMP has recommended atripla
for the treatment of
human immunodeficiency virus-...stance to any of the three components contained
prior to initiation of their first antiretroviral ...
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
...fection in adults. With this Notice of
becomes the first once-daily single tablet regimen...apy or in combination
with other antiretrovirals. atripla
combines SUSTIVA(R) (efavirenz), manufactured by B... three-drug
regimen in a single once-daily pill." atripla
was developed through a joint venture partnership ...
Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
...once daily lifesaving HIV
treatment, Atripla, in developing countries. When atripla
approval from the Food and Drug Administration (FDA) in July... 2006. Efforts made by AHF to clarify what
countries currently can purchase atripla
at the announced $613 per patient
per year access price have gone unanswere...